Kalincik T,; Brown JW,; Robertson N,; Willis M,; Scolding N,; Simó, Magdolna
(2017)
BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies ...